Ether

Ether

SCHEMBL21144490

C/C=C\c1ccccc1OC(=O)C(CC(=O)O)S(=O)(=O)O.CCOCC

nearest known ligand 0.38

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.38
MEN1 O00255 3/20 0.38
NFE2L2 Q16236 2/20 0.37
TFEB P19484 1/20 0.37
MAPT P10636 6/20 0.36
LMNA P02545 5/20 0.36
PLIN1 O60240 1/20 0.36
POLB P06746 1/20 0.36
PLIN5 Q00G26 1/20 0.36
ABHD5 Q8WTS1 1/20 0.36
KDM4E B2RXH2 6/20 0.35
ALDH1A1 P00352 4/20 0.35
NPSR1 Q6W5P4 3/20 0.35
HTT P42858 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
NPC1 O15118 3/20 0.34
RAB9A P51151 3/20 0.34
BCHE P06276 1/20 0.34
PTGDR2 Q9Y5Y4 1/20 0.34
SMN1; SMN2 Q16637 3/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ether SCHEMBL2843584 0.83 NFE2L2 (0.39) KMT2AMEN1NFE2L2MAPTLMNA
SCHEMBL21144492 0.81 MEN1 (0.41) KMT2AMEN1NFE2L2TFEBMAPT
Ether SCHEMBL4785780 0.79 ALDH1A1 (0.40) KMT2AMEN1LMNAKDM4EALDH1A1
Ether SCHEMBL2872980 0.78 ALDH1A1 (0.39) KMT2AMEN1LMNAKDM4EALDH1A1
SCHEMBL18141022 0.76 KMT2A (0.40) KMT2AMEN1MAPTPOLBKDM4E
SCHEMBL28245082 0.75 KMT2A (0.39) KMT2AMEN1MAPTPOLBKDM4E
Ether SCHEMBL21110865 0.75 MEN1 (0.40) KMT2AMEN1NFE2L2TFEBMAPT
SCHEMBL18140313 0.75 TDP1 (0.43) POLBL3MBTL1SMN1; SMN2ATMTDP1
Ether SCHEMBL21111047 0.74 MEN1 (0.40) KMT2AMEN1NFE2L2TFEBMAPT
SCHEMBL28245071 0.74 TDP1 (0.42) POLBL3MBTL1SMN1; SMN2ATMTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11578028-B2 Surfactant composition DAI-ICHI KOGYO SEIYAKU CO., LTD. (JP) 2023-02-14 US claimed
WO-2021198866-A1 BLUE CATHODIC ELECTRODEPOSITION (CED) COATING COMPOSITION KANSAI NEROLAC PAINTS LIMITED (IN) 2021-10-07 WO claimed
US-20200331830-A1 SURFACTANT COMPOSITION DAI-ICHI KOGYO SEIYAKU CO., LTD. (JP) 2020-10-22 US claimed
US-20190217265-A1 SURFACTANT COMPOSITION DAI-ICHI KOGYO SEIYAKU CO., LTD. (JP) 2019-07-18 US claimed
WO-2021198866-A1 BLUE CATHODIC ELECTRODEPOSITION (CED) COATING COMPOSITION KANSAI NEROLAC PAINTS LIMITED (IN) 2021-10-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11578028-B2 Surfactant composition CHRM1, DEGS1, ASH2L KMT2A 866/4885MEN1 2495/4885NFE2L2 4164/4885
US-20200331830-A1 SURFACTANT COMPOSITION CHRM1, DEGS1, ASH2L KMT2A 866/4885MEN1 2495/4885NFE2L2 4164/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.